Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19155933 | 0.85 | CYP2C9 (0.39) | CYP2C9PSMB5MMEKMT2AMEN1 | |
| SCHEMBL18513200 | 0.85 | CYP2C9 (0.39) | CYP2C9TDP1PSMB5MMEKMT2A | |
| SCHEMBL16298562 | 0.82 | CYP2C9 (0.43) | CYP2C9ALDH1A1TDP1PSMB5MME | |
| SCHEMBL12835663 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TDP1 | |
| SCHEMBL13857484 | 0.82 | CYP2C9 (0.43) | CYP2C9ALDH1A1PSMB5KMT2AMEN1 | |
| SCHEMBL20099254 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TDP1MME | |
| SCHEMBL19361986 | 0.78 | CYP2C9 (0.41) | CYP2C9ALDH1A1PSMB5KMT2AMEN1 | |
| SCHEMBL13122874 | 0.78 | CYP2C9 (0.41) | CYP2C9ALDH1A1TDP1PSMB5MME | |
| SCHEMBL14131182 | 0.78 | CYP2C9 (0.41) | CYP2C9ALDH1A1TDP1PSMB5MME | |
| SCHEMBL25467031 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | CYP2C9 3412/4885ALDH1A1 2605/4885TDP1 3618/4885 |
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | CYP2C9 4151/4885ALDH1A1 3686/4885TDP1 4347/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | CYP2C9 1556/4885ALDH1A1 2760/4885TDP1 4589/4885 |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | APOB, APOL1, LDLR | CYP2C9 4017/4885ALDH1A1 1781/4885TDP1 2818/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | CYP2C9 3412/4885ALDH1A1 2605/4885TDP1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.